Literature DB >> 22830364

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

Ian Williams1, Duncan Churchill, Jane Anderson, Marta Boffito, Mark Bower, Gus Cairns, Kate Cwynarski, Simon Edwards, Sarah Fidler, Martin Fisher, Andrew Freedman, Anna Maria Geretti, Yvonne Gilleece, Rob Horne, Margaret Johnson, Saye Khoo, Clifford Leen, Neal Marshall, Mark Nelson, Chloe Orkin, Nicholas Paton, Andrew Phillips, Frank Post, Anton Pozniak, Caroline Sabin, Roy Trevelion, Andrew Ustianowski, John Walsh, Laura Waters, Edmund Wilkins, Alan Winston, Mike Youle.   

Abstract

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection with antiretroviral therapy (ART). The scope includes: (i) guidance on the initiation of ART in those previously naïve to therapy; (ii)support of patients on treatment; (iii) management of patients experiencing virological failure; and (iv) recommendations in specific patient populations where other factors need to be taken into consideration. The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22830364     DOI: 10.1111/j.1468-1293.2012.01029.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  62 in total

Review 1.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition.

Authors:  S MacCarthy; D R Bangsberg; G Fink; M Reich; S Gruskin
Journal:  HIV Med       Date:  2013-09-11       Impact factor: 3.180

3.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

4.  [Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].

Authors:  Jorge Alave; Jorge Paz; Elsa González; Miguel Campos; Martin Rodríguez; James Willig; Juan Echevarría
Journal:  Rev Chilena Infectol       Date:  2013-02       Impact factor: 0.520

5.  Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Authors:  Luke C Swenson; Bryan Cobb; Anna Maria Geretti; P Richard Harrigan; Mario Poljak; Carole Seguin-Devaux; Chris Verhofstede; Marc Wirden; Alessandra Amendola; Jurg Boni; Thomas Bourlet; Jon B Huder; Jean-Claude Karasi; Snjezana Zidovec Lepej; Maja M Lunar; Odette Mukabayire; Rob Schuurman; Janez Tomazic; Kristel Van Laethem; Linos Vandekerckhove; Annemarie M J Wensing
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

6.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

7.  An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis?

Authors:  Mark D Russell; Deepak Singh-Ranger; James Crosbie
Journal:  BMJ Case Rep       Date:  2014-03-26

8.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Authors:  Beatriz Grinsztejn; Mina C Hosseinipour; Heather J Ribaudo; Susan Swindells; Joseph Eron; Ying Q Chen; Lei Wang; San-San Ou; Maija Anderson; Marybeth McCauley; Theresa Gamble; Nagalingeshwaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Marineide Gonçalves de Melo; Kenneth H Mayer; Susan H Eshleman; Estelle Piwowar-Manning; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Ian Sanne; Joel Gallant; Irving Hoffman; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Diane Havlir; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2014-03-04       Impact factor: 25.071

9.  Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.

Authors:  Luis F Lopez-Cortes; Rosa Ruiz-Valderas; Elena Sánchez-Rivas; Amparo Lluch; Alicia Gutierrez-Valencia; Almudena Torres-Cornejo; Omar J Benmarzouk-Hidalgo; Pompeyo Viciana
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Margaret T May; Suzanne M Ingle; Dominique Costagliola; Amy C Justice; Frank de Wolf; Matthias Cavassini; Antonella D'Arminio Monforte; Jordi Casabona; Robert S Hogg; Amanda Mocroft; Fiona C Lampe; François Dabis; Gerd Fätkenheuer; Timothy R Sterling; Julia del Amo; M John Gill; Heidi M Crane; Michael S Saag; Jodie Guest; Hans-Reinhard Brodt; Jonathan A C Sterne
Journal:  Int J Epidemiol       Date:  2013-04-18       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.